EWS/ETS proteins promote expression and regulate function of the homeodomain transcription factor BRN3A

Oncogene

Volumn 29, Issue 21, 2010, Pages 3134-3145

  Gascoyne, D M ^a   Dunne, J ^b   Behjati, S ^a   Sebire, N J ^c   Anderson, J ^a   Latchman, D S ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

BRN3A; EFT; Ewing's sarcoma; EWS ETS; POU4F1

Indexed keywords

RNA BINDING PROTEIN EWS; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR POU4F1; TUMOR MARKER;

ARTICLE; AUTOREGULATION; CANCER CELL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; EWING FAMILY TUMORS; EWING SARCOMA; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; NEUROBLASTOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

CELL DIFFERENTIATION; GENES, REPORTER; HUMANS; LUCIFERASES; NEUROBLASTOMA; NEURONS; PLASMIDS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-ETS-1; RECOMBINANT FUSION PROTEINS; RHABDOMYOSARCOMA; RNA-BINDING PROTEIN EWS; SARCOMA, EWING'S; TRANSCRIPTION FACTOR BRN-3A;

EID: 77952959074     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.72     Document Type: Article

References (50)

1. Arvand A, Denny CT. (2001). Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20: 5747-5754.
2. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M et al. (1994). Dna-binding and transcriptional activation properties of the Ews-Fli-1 fusion protein resulting from the T(11;22) translocation in Ewing sarcoma. Mol Cell Biol 14: 3230-3241.
3. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen YD et al. (2005). Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65: 9226-9235.
4. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W et al. (2009). GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 284: 9074-9082.
5. Bradford AP, Wasylyk C, Wasylyk B, GutierrezHartmann A. (1997). Interaction of Ets-1 and the POU-homeodomain protein GHF-1/Pit-1 reconstitutes pituitary-specific gene expression. Mol Cell Biol 17: 1065-1074.
6. Collum RG, Fisher PE, Datta M, Mellis S, Thiele C, Huebner K et al. (1992). A novel Pou homeodomain gene specifically expressed in cells of the developing mammalian nervous-system. Nucleic Acids Res 20: 4919-4925.
7. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE et al. (2001). Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57(KIP2) and c-Myc expression. Oncogene 20: 3258-3265.
8. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M et al. (1992). Gene fusion with an Ets Dna-binding domain caused by chromosome-translocation in human tumors. Nature 359: 162-165.
9. Eliazer S, Spencer J, Ye D, Olson E, Ilaria RL. (2003). Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol Cell Biol 23: 482-492.
10. Eng SR, Gratwick K, Rhee JM, Fedtsova N, Gan L, Turner EE. (2001). Defects in sensory axon growth precede neuronal death in Brn3a-deficient mice. J Neurosci 21: 541-549.
11. Ensor E, Smith MD, Latchman DS. (2001). The BRN-3A transcription factor protects sensory but not sympathetic neurons from programmed cell death/apoptosis. J Biol Chem 276: 5204-5212.
12. Fedtsova NG, Turner EE. (1995). Brn-3.0 expression identifies early postmitotic CNS neurons and sensory neural precursors. Mech Dev 53: 291-304.
13. Frass B, Vassen L, Moroy T. (2002). Gene expression of the POU factor Brn-3a is regulated by two different promoters. Biochim Biophys Acta 1579: 207-213.
14. Fukuma M, Okita H, Hata J, Umezawa A. (2003). Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 22: 1-9.
15. Gascoyne DM, Thomas GR, Latchman DS. (2004). The effects of Brn-3a on neuronal differentiation and apoptosis are differentially modulated by EWS and its oncogenic derivative EWS/Fli-1. Oncogene 23: 3830-3840.
16. Gonzalez I, Andreu EJ, Panizo A, Inoges S, Fontalba A, Fernandez-Luna JL et al. (2004). Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell Factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apopto-sis. Clin Cancer Res 10: 751-761.
17. Hahm KB, Cho KN, Lee C, Im YH, Chang J, Choi SG et al. (1999). Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 23: 222-227.
18. Hippenmeyer S, Vrieseling E, Sigrist M, Portmann T, Laengle C, Ladle DR et al. (2005). A developmental switch in the response of DRG neurons to ETS transcription factor signaling. PLoS Biol 3: 878-890.
19. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. (2005a). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65: 8984-8992.
20. Hu-Lieskovan S, Zhang JS, Wu LT, Shimada H, Schofield DE, Triche TJ. (2005b). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res 65: 4633-4644.
21. Jaishankar S, Zhang J, Roussel MF, Baker SJ. (1999). Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity. Oncogene 18: 5592-5597.
22. Kim S, Denny CT, Wisdom R. (2006). Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol Cell Biol 26: 2467-2478.
23. Landuzzi L, De Giovanni C, Nicoletti G, Rossi I, Ricci C, Astolfi A et al. (2000). The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol 157: 2123-2131.
24. Lanier J, Quina LA, Eng SR, Cox E, Turner EE. (2007). Brn3a target gene recognition in embryonic sensory neurons. Dev Biol 302: 703-716.
25. Leblond Francillard M, Picon A, Bertagna X, deKeyzer Y. (1997). High expression of the POU factor Brn3a in aggressive neuroendo-crine tumors. J Clin Endocrinol Metab 82: 89-94.
26. Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL et al. (2007). Preclinical in vivo study of new insulin-like growth factor-1 receptor\specific inhibitor in Ewing's sarcoma. Clin Cancer Res 13: 1322-1330.
27. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. (1997). EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 17: 495-497.
28. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O et al. (1993). Ewing sarcoma 11-22 translocation produces a chimeric transcription factor that requires the Dna-binding domain encoded by fli1 for transformation. Proc Natl Acad Sci USA 90: 5752-5756.
29. McEvilly RJ, Erkman L, Luo L, Sawchenko PE, Ryan AF, Rosenfeld MG. (1996). Requirement for Brn-3.0 in differentiation and survival of sensory and motor neurons. Nature 384: 574-577.
30. Nakatani F, Tanaka K, Sakimura R, Matsumoto Y, Matsunobu T, Li X et al. (2003). Identification of p21(WAF1/CIP1) as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 278: 15105-15115.
31. Perez-Sanchez C, Budhram-Mahadeo VS, Latchman DS. (2002). Distinct promoter elements mediate the co-operative effect of Brn-3a and p53 on the p21 promoter and their antagonism on the Bax promoter. Nucleic Acids Res 30: 4872-4880.
32. Prieur A, Tirode F, Cohen P, Delattre O. (2004). EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24: 7275-7283.
33. Radig K, Schneider-Stock R, Rose I, Mittler U, Oda Y, Roessner A. (1998). p53 and ras mutations in Ewing's sarcoma. Pathol Res Pract 194: 157-162.
34. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C et al. (2005). Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65: 11459-11468.
35. Riggi N, Suva ML, Cironi L, Provero P, Tercier S, Joseph JM et al. (2008). EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal cells. Cancer Res 68: 2176-2185.
36. Rorie CJ, Thomas VD, Chen PC, Pierce HH, O'Bryan JP, Weissman BE. (2004). The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res 64: 1266-1277.
37. Smith MD, Dawson SJ, Latchman DS. (1997). The Brn-3a transcription factor induces neuronal process outgrowth and the coordinate expression of genes encoding synaptic proteins. Mol Cell Biol 17: 345-354.
38. Smith R, Owen LA, Trem DJ, Wong JS, Jennifer SW, Golub TR et al. (2006). Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 9: 405-416.
39. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. (1997). EWS-FLi1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 99: 239-247.
40. Theil T, Mcleanhunter S, Zornig M, Moroy T. (1993). Mouse Brn-3 family of pou transcription factors\a new aminoterminal domain is crucial for the oncogenic activity of Brn-3A. Nucleic Acids Res 21: 5921-5929.
41. Thiele CJ. (1990). Pediatric peripheral neuroectodermal tumors, oncogenes, and differentiation. Cancer Invest 8: 629-639.
42. Torchia EC, Jaishankar S, Baker SJ. (2003). Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res 63: 3464-3468.
43. Trieu M, Ma A, Eng SR, Fedtsova N, Turner EE. (2003). Direct autoregulation and gene dosage compensation by POU-domain transcription factor Brn3a. Development 130: 111-121.
44. Trieu M, Rhee JM, Fedtsova N, Turner EE. (1999). Autoregulatory sequences are revealed by complex stability screening of the mouse brn-3.0 locus. J Neurosci 19: 6549-6558.
45. Welford SM, Hebert SP, Deneen B, Arvand A, Denny CT. (2001). DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 276: 41977-41984.
46. Wood JN, Bevan SJ, Coote PR, Dunn PM, Harmar A, Hogan P et al. (1990). Novel cell-lines display properties of nociceptive sensory neurons. Proc R Soc Lond B Biol Sci 241: 187-194.
47. Xiang MQ, Gan L, Zhou LJ, Klein WH, Nathans J. (1996). Targeted deletion of the mouse POU domain gene Brn-3a causes a selective loss of neurons in the brainstem and trigeminal ganglion, uncoordinated limb movement, and impaired suckling. Proc Natl Acad Sci USA 93: 11950-11955.
48. Yamaguchi S, Yamazaki Y, Ishikawa Y, Noriyoshi KI, Mukai H, Nakamura T. (2005). EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosomes Cancer 43: 217-222.
49. Yeny CT, Eliazer S, Xiang LL, Richardson JA, Ilaria RL. (2005). Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors. Cancer Res 65: 8698-8705.
50. Zhang JS, Hu SW, Schofield DE, Sorensen PHB, Triche TJ. (2004). Selective usage of D-type cyclins by Ewing's tumors and rhabdo-myosarcomas. Cancer Res 64: 6026-6034.